This meeting took place in 2018
For a complete list of the meetings for the upcoming/current season, see our meeting list, or search for a meeting.
T Cell Dysfunction, Cancer and Infection (A3)
Organizer(s) Daniel C. Douek, W. Nicholas Haining and Jedd D. Wolchok
January 16—20, 2018
Beaver Run Conference Center • Breckenridge, CO USA
Discounted Abstract Deadline: Sep 21, 2017
Abstract Deadline: Oct 19, 2017
Scholarship Deadline: Sep 21, 2017
Discounted Registration Deadline: Nov 20, 2017
Sponsored by Amgen Inc., Incyte Corporation, Juno Therapeutics, Merck & Co., Inc., Regeneron Pharmaceuticals, Inc., Surface Oncology and TESARO, Inc.
Summary of Meeting:
T cell exhaustion is an acquired state of T cell dysfunction, associated with reduced T cell function, sustained expression of inhibitory receptors and a transcriptional state that is distinct from memory and effector T cells. T cell exhaustion is now recognized as a defining feature not only of chronic infections such as HIV, malaria and tuberculosis, but also of cancer. As a result, the search for effective approaches to reverse T cell exhaustion is the focus of immense therapeutic development. However, the similarities and differences between T cell dysfunction arising in chronic infection and tumors are not fully understood. Moreover, opportunities to identify new therapeutic approaches to reverse dysfunction based on parallels between the two disease states remain to be explored. This meeting will focus on the comparative biology and clinical therapeutics of T cell dysfunction in chronic viral infection and cancer. Drawing on leaders in fundamental T cell biology, computational science and clinical investigation, it will focus on common features and distinctive aspects of T cell dysfunction in cancer and chronic infection. The meeting will have broad relevance for T cell biology, tumor immunity, infectious disease and therapeutic development.
View Meeting Program
T cell exhaustion is an acquired state of T cell dysfunction, associated with reduced T cell function, sustained expression of inhibitory receptors and a transcriptional state that is distinct from memory and effector T cells. T cell exhaustion is now recognized as a defining feature not only of chronic infections such as HIV, malaria and tuberculosis, but also of cancer. As a result, the search for effective approaches to reverse T cell exhaustion is the focus of immense therapeutic development. However, the similarities and differences between T cell dysfunction arising in chronic infection and tumors are not fully understood. Moreover, opportunities to identify new therapeutic approaches to reverse dysfunction based on parallels between the two disease states remain to be explored. This meeting will focus on the comparative biology and clinical therapeutics of T cell dysfunction in chronic viral infection and cancer. Drawing on leaders in fundamental T cell biology, computational science and clinical investigation, it will focus on common features and distinctive aspects of T cell dysfunction in cancer and chronic infection. The meeting will have broad relevance for T cell biology, tumor immunity, infectious disease and therapeutic development.
View Meeting Program
Scholarships/Awards
Keystone Symposia Donor Funds Scholarship Recipients
Kristoffer Haurum Johansen
Technical University of Denmark, Denmark
National Cancer Institute (NCI) Scholarship Recipients
Jean-Christophe Beltra
University of Pennsylvania, USA
Brian Christopher Miller
Dana-Farber Cancer Institute, USA
